---
figid: PMC6200076__ott-11-7095Fig1
figtitle: Mechanisms of resistance to BRAF and MEK inhibitors and clinical update
  of US Food and Drug Administration-approved targeted therapy in advanced melanoma
organisms:
- Homo sapiens
- Mus musculus
- Diaporthe sclerotioides
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC6200076
filename: ott-11-7095Fig1.jpg
figlink: /pmc/articles/PMC6200076/figure/f1-ott-11-7095/
number: F1
caption: 'MAPK–PI3K–Akt pathway and BRAFV600 mutation in melanoma.Notes: MAPK pathway
  in normal cells (left), where growth factors bound to RTK result in phosphorylation
  of Ras kinase, which further activates downstream kinases (Raf–MEK–ERK and PI3K–Akt–mTOR)
  and regulates the activities of several transcription factors responsible for cell
  growth, survival, and proliferation. BRAFV600 mutations in melanoma lead to constitutive
  activation of the MAPK pathway, which leads to uncontrolled cell survival, growth,
  and proliferation in malignant melanoma (right) that might be reversed, at least
  temporarily, by treatment with BRAF inhibitors.'
papertitle: Mechanisms of resistance to BRAF and MEK inhibitors and clinical update
  of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
reftext: Sunilkumar Kakadia, et al. Onco Targets Ther. 2018;11:7095-7107.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9677336
figid_alias: PMC6200076__F1
figtype: Figure
redirect_from: /figures/PMC6200076__F1
ndex: 382ed0cb-deaa-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6200076__ott-11-7095Fig1.html
  '@type': Dataset
  description: 'MAPK–PI3K–Akt pathway and BRAFV600 mutation in melanoma.Notes: MAPK
    pathway in normal cells (left), where growth factors bound to RTK result in phosphorylation
    of Ras kinase, which further activates downstream kinases (Raf–MEK–ERK and PI3K–Akt–mTOR)
    and regulates the activities of several transcription factors responsible for
    cell growth, survival, and proliferation. BRAFV600 mutations in melanoma lead
    to constitutive activation of the MAPK pathway, which leads to uncontrolled cell
    survival, growth, and proliferation in malignant melanoma (right) that might be
    reversed, at least temporarily, by treatment with BRAF inhibitors.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Braf
  - Braf-rs1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Akt1
  - Mtor
  - Ephb2
  - Mapk1
  - Sgk1
  - Mdk
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - BRAF
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - SGK1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - Tie
  - Ras85D
  - InR
  - Ras64B
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - Erk7
  - rl
  - Thor
  - Dsor1
  - Mtk
  - braf
  - si:dkey-222f8.3
  - rab1ab
  - mtor
  - sgk1
  - eif4ebp3l
  - Dabrafenib
  - Vemurafenib
  - Cancer
---
